Abstract:Pepducins are cell-penetrating, membrane-tethered lipopeptides designed to target the intracellular region of a G protein-coupled receptor (GPCR) in order to allosterically modulate the receptor's signaling output. In this proof-of-concept study, we explored the pain-relief potential of a pepducin series derived from the first intracellular loop of neurotensin receptor type 1 (NTS1), a class A GPCR that mediates many of the effects of the neurotensin (NT) tridecapeptide, including hypothermia, hypotension and analgesia. We used BRET-based biosensors to determine the pepducins' ability to engage G protein signaling pathways associated with NTS1 activation. We observed partial Gαq and Gα13 activation at a 10 µM concentration, indicating that these pepducins may act as allosteric agonists of NTS1. Additionally, we used surface plasmon resonance (SPR) as a label-free assay to monitor pepducin-induced responses in CHO-K1 cells stably expressing hNTS1. This whole-cell integrated assay enabled us to subdivide our pepducin series into three profile response groups. In order to determine the pepducins' antinociceptive potential, we then screened the series in an acute pain model (tail-flick test) by measuring tail withdrawal latencies to a thermal nociceptive stimulus, following intrathecal (i.t.) pepducin administration (275 nmol/kg). We further evaluated promising pepducins in a tonic pain model (formalin test), as well as in neuropathic (Chronic Constriction Injury) and inflammatory (Complete Freund's Adjuvant) chronic pain models. We report one pepducin, PP-001, that consistently reduced rat nociceptive behaviors, even in chronic pain paradigms. Finally, we designed a TAMRA-tagged version of PP-001 and found by confocal microscopy that the pepducin reached the rat dorsal root ganglia post i.t. injection, thus potentially modulating the activity of NTS1 at this location to produce its analgesic effect. Altogether, these results suggest that NTS1-derived pepducins may represent a promising strategy in pain-relief.

Cell-penetrating pepducins targeting the neurotensin receptor type 1 relieve pain

PD-1: A New Candidate Target for Analgesic Peptide Design

A marine analgesic peptide, Contulakin-G, and neurotensin are distinct agonists for neurotensin receptors: uncovering structural determinants of desensitization properties

Metabolically stable neurotensin analogs exert potent and long-acting analgesia without hypothermia

Intrathecal administration of NTS1 agonists reverses nociceptive behaviors in a rat model of neuropathic pain

Analgesic Microneedle Patch For Neuropathic Pain Therapy

Nanomedicines Targeting Signaling of Protease-activated Receptor 2 in Organelles Provide Sustained Analgesia

De Novo Design of Peptidic Positive Allosteric Modulators Targeting TRPV1 with Analgesic Effects

A Synthetic Cell-Penetrating Peptide Antagonizing Trka Function Suppresses Neuropathic Pain in Mice

Targeting Neuropathic Pain: Pathobiology, Current Treatment and Peptidomimetics as a New Therapeutic Opportunity

Pain relief devoid of opioid side effects following central action of a silylated neurotensin analog

A Synthetic Peptide Disturbing GluN2A/SHP1 Interaction in Dorsal Root Ganglion Attenuated Pathological Pain

Development of ProTx-II Analogues as Highly Selective Peptide Blockers of Nav1.7 for the Treatment of Pain

Molecular design, construction and analgesic mechanism insights into the novel transdermal fusion peptide ANTP-BgNPB

GpTx‐1 and [ala5, Phe6, Leu26, Arg28]GpTx‐1, Two Peptide NaV1.7 Inhibitors: Analgesic and Tolerance Properties at the Spinal Level

Enkephalin-mediated modulation of basal somatic sensitivity by regulatory T cells in mice

Novel therapeutics based on recombinant botulinum neurotoxins to normalize the release of transmitters and pain mediators

(399) A Membrane-Delimited N-myristoylated CRMP2 Peptide Aptamer Inhibits CaV2.2 Trafficking and Reverses Post-Operative Pain Behaviors

Identification of an adenylyl cyclase inhibitor for treating neuropathic and inflammatory pain

Neuropeptide S Produces Antinociceptive Effects at the Supraspinal Level in Mice

δ-Ctenitoxin-Pn1a, a Peptide from Phoneutria nigriventer Spider Venom, Shows Antinociceptive Effect Involving Opioid and Cannabinoid Systems, in Rats